These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNα2b. Chung E; Park K; Kim JH; Han NI; Lee YS; Bae SH; Park CH Korean J Intern Med; 2017 Nov; 32(6):1098-1100. PubMed ID: 28823117 [No Abstract] [Full Text] [Related]
12. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Teta D; Lüscher BL; Gonvers JJ; Francioli P; Phan O; Burnier M Nephrol Dial Transplant; 2005 May; 20(5):991-3. PubMed ID: 15741205 [No Abstract] [Full Text] [Related]
13. Erythema gyratum repens induced by pegylated interferon alfa for chronic hepatitis C. Rongioletti F; Fausti V; Parodi A Arch Dermatol; 2012 Oct; 148(10):1213-4. PubMed ID: 23069974 [No Abstract] [Full Text] [Related]
18. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C. Colomba C; Rubino R; Siracusa L; Mazzola G; Titone L J Antimicrob Chemother; 2012 Jan; 67(1):249-50. PubMed ID: 21965434 [No Abstract] [Full Text] [Related]
19. Pegylated interferon and ribavirin therapy for hepatitis C causing cataract. Ku JY; Sharma A Clin Exp Ophthalmol; 2009 Sep; 37(7):743-5. PubMed ID: 19788675 [No Abstract] [Full Text] [Related]
20. Fulminant type 1 diabetes caused by peginterferon α-2a therapy in hepatitis C. Zheng Y; Wang Z; Xie Z; Dai R; Zhou Z J Diabetes; 2018 May; 10(5):419-420. PubMed ID: 29265717 [No Abstract] [Full Text] [Related] [Next] [New Search]